Graf, Helen
Gräfe, Caroline
Bruegel, Mathias
Happich, Felix L.
Wustrow, Vassilissa
Wegener, Aljoscha
Wilfert, Wolfgang
Zoller, Michael
Liebchen, Uwe
Paal, Michael
Scharf, Christina
Clinical trials referenced in this document:
Documents that mention this clinical trial
Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study
https://doi.org/10.1186/s13613-023-01198-7
Extracorporeal Elimination of Pro- and Anti-inflammatory Modulators by the Cytokine Adsorber CytoSorb® in Patients with Hyperinflammation: A Prospective Study
https://doi.org/10.1007/s40121-024-01028-8
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2021_EKEA.101)
Article History
Received: 1 July 2024
Accepted: 30 July 2024
First Online: 18 August 2024
Declarations
:
: Christina Scharf got speaker fees from CytoSorbents Europe GmbH. Michael Zoller received consulting honoraries from CytoSorbents Europe GmbH. Uwe Liebchen received consulting honoraries from CytoSorbents Europe GmbH and Medows and was part of an advisory board of Roche Diagnostics International Ltd. Helen Graf, Caroline Gräfe, Mathias Bruegel, Felix L. Happich, Vassilissa Wustrow, Aljoscha Wegener, Wolfgang Wilfert, and Michael Paal have nothing to disclose.
: Ethical approval was obtained from the ethical review committee of the Ludwig-Maximilians-Universität (registration number 21-236). Written informed consent was obtained from the patients or their legal representatives in line with the vote of the review board prior to study inclusion. This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.